
This article is sponsored content brought to you by AVet Health.
Osteoarthritis is a commonly diagnosed joint disease in dogs. It is a degenerative joint disease that involves inflammation of synovial joints and the progressive deterioration of joint cartilage over time. This leads to pain and loss of joint mobility and function.
Many factors are believed to contribute to the development of osteoarthritis, with both genetics and lifestyle factors playing a role. Osteoarthritis development often occurs following trauma or increased wear and tear, which can occur in athletic dogs, obese dogs, or dogs that have abnormal development of their joints.
Here, Dr Cybele answers some questions about managing osteoarthritis using a multimodal approach:
Can you provide an overview of what a multimodal approach is?
A multimodal approach means that a tailored combination of different products, medications, therapies and strategies are used to achieve the best possible comfort and mobility outcomes for an individual dog – while also minimising the side effects that can be associated with medications such as non-steroidal anti-inflammatory drugs (NSAIDs).
What are some of the modes that can be included?
The different modes in a multimodal approach can include weight management, exercise modification and environmental modification – such as providing ramps and elevated food bowls – as well as a combination of mediations and other products and therapies.
Common medications used in a multi-modal approach include opioids, gabapentinoids and NSAIDs such as Meloxicam. These are important for managing pain.
Other products in a multimodal toolbox include injectable chondroprotective agents and nutraceuticals, which may serve to support joint cartilage and help slow the progression of osteoarthritis.
Therapies in a multimodal approach can include physiotherapy, laser therapy and acupuncture.
Some tools of the future that we may see increasingly used in a multimodal approach include structure modifying osteoarthritis drugs – such as mesenchymal stem cells and platelet-rich plasma – and gene therapy.
What are some of the things you consider when talking to an owner about osteoarthritis?
Firstly, I acknowledge that osteoarthritis and its management can be a complex topic for an owner – and the nature of the initial conversation can vary markedly depending on the level of pain and loss of mobility that a particular dog is demonstrating.
I do like to introduce the concept of a multimodal approach to osteoarthritis management as early as possible in the conversation. I acknowledge that this can be a lot for an owner to take in, so in the discussion, I focus on the particular tools that I recommend at this particular time for this particular patient.
While the concept of a multimodal approach can be a lot for an owner to process, I can also see that it is empowering because the focus is on what the owner can do to play a meaningful role in managing the comfort of their dog.
One key aspect I also try to highlight is the progressive and seasonal nature of the disease. I explain that this progressive and seasonal nature means we must continuously work together to monitor the comfort and mobility of their dog – and modify the combination of medications, products and therapies used in response to any changes.
And I write the current plan down. This is why we created the Osteoarthritis Management Planner. At AVet Health, we appreciate that managing osteoarthritis is complex and that vets have a lot happening on any given day. Our goal with the planner is to help vets by creating a resource that makes communicating this topic to owners that little bit easier.
Visit AVet Health


